TARS · Tarsus Pharmaceuticals, Inc.

Track TARS — free

$75.07 -0.40 (-0.52%)

Russell 2000 member Rebalance outlook locked

Market Cap

$3.32B

43.88M

Volume · Oct 2 82.83K Avg daily vol (3M) 943.54K

Up next

Next earnings call

Nov 5, 2026 Est · unconfirmed · in 5 wks

Latest filing: 10-Q

filed Aug 6, 2026

Q2 2026 earnings call transcript

call held Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$606.33M

Trailing 12 months

Net income (TTM)

−$46.48M

Trailing 12 months

Revenue growth YoY

+69.4%

Year over year

Operating margin

-8.0%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

1.7%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$376.93M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+2.4%

Year over year · more shares

Price change (1Y)

+32.3%

Trailing year

Short interest

14.0%

Latest settlement · 6.6 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 16.4 · calm Equity put/call 0.57

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +10%

above

Price vs 50-day avg +5%

above

RSI (14) 48

neutral

MACD trend Negative

52-week position 56%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return −9%

trailing

6-month return +4%

trailing

YTD return −8%

this year

Relative strength −8%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $72 › 200d $69 — 50d above 200d

Institutional flow Accumulating

+2% holders QoQ · +40 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

13.96% of float · ▲ +1.9% MoM · 6.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

258 holders — near 3-yr high, broad support

Squeeze score 71

high risk · 0–100

Fundamentals

Strong

Revenue growth +147%

Y/Y

EPS growth +48%

Y/Y

Free cash flow $-22.3M

Balance sheet $111.2M

net cash

Quant / Vol

risk profile

Very High

Volatility 46%

annualized · 1-yr

Max drawdown −32%

past year

ATR 4.0%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Aug 6, 2026

XDEMVY net product sales · full-year 2026 Initiated $685M – $705M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

1 · 4 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+10% Bullish

Price vs 50-day avg

+5% Bullish

RSI (14)

48 Neutral

MACD trend

Negative Bearish

52-week position

56% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $72 › 200d $69 — 50d above 200d

Institutional flow Accumulating

+2% holders QoQ · +40 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

13.96% of float · ▲ +1.9% MoM · 6.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

258 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $56 Now $75 · 56% Range high $91

vs 200-day avg +10% vs 50-day avg +5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
net product sales	$173.9M	the second quarter of 2026 filing	+69.4%

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
TARS Tarsus Pharmaceuticals, Inc. this stock	$3.32B	-7.8%	+146.7%	—	14.0%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+11.8%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-4.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+540.7%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

258

% held: 110.0%
Net QoQ: +2.6M sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

240

View

Short & Settlement

Short Interest Rising

Shares short

6.1M

Days to cover: 6.6d
Change: +116.3K sh

View

Short Volume

Short vol %

71%

As of: Oct 1, 2026

Short Total

View

Fails to Deliver

FTD shares

249

Value: $22.6K
As of: Sep 8, 2026

View

Off-Exchange

Off-exchange %

52.8%

Week of: Aug 24, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$451.4M

Net income (FY): $-66.4M
EPS diluted: $-1.59

View

Filings

SEC Filings

Latest

8-K

Filed: Sep 10, 2026
This year: 20

View

Proposed Sales

Value

$387.9K

Shares: 4.6K
Filed: Sep 4, 2026

View

Earnings & Events

Webcasts

Last webcast

Aug 6, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
TARS	-0.7%	-8.8%	+4.0%	-4.0%	-7.8%
SPY	-0.4%	-0.2%	+12.4%	+0.2%	+12.0%
vs SPY	-0.2%	-8.7%	-8.4%	-4.2%	-19.9%

Key facts CIK 1819790 CUSIP 87650L103 13F (30d) 7 filings 7 filers Visit website Investor relations

TARS · Tarsus Pharmaceuticals, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance